CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 139 enrolled
Drug / intervention
Rocuronium 0.3mg/kg/hr +1 moredrug
Likely dose
Rocuronium 0.3mg/kg/hrfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03808077
NCT03808077Phase 2Active
CompareCT.gov

A Randomized Controlled Trial to Compare the Effectiveness of Deep vs. Moderate Neuromuscular Blockade in Reducing Postoperative Pain and Intra-Abdominal Insufflation Pressure During Minimally Invasive Robotic Prostatectomy

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 17, 2019·Updated Mar 9, 2026

In Brief

A Phase 2 clinical trial evaluating Rocuronium 0.3mg/kg/hr and Rocuronium 1.5mg/kg/hr for Prostate Cancer. Active but no longer recruiting, targeting 139 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic prostate surgery with deep neuromuscular blockade (NMB), compared with moderate NMB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
201920202021202220232024202520262027
First PostedJan 17, 2019
Enrollment StartJan 14, 2019
Primary CompletionOct 11, 2024
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 7.5 years ago

Interventions

Rocuronium 0.3mg/kg/hrdrug

The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.003 mg/kg/min or 0.18mg/kg/hr).

Rocuronium 1.5mg/kg/hrdrug

The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.006mg/kg/min or 0.35mg/kg/hr).